You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美迪西(688202.SH):公司擁有全面的臨牀前新藥研發能力及豐富的研發經驗
格隆匯 08-07 07:14

格隆匯8月7日丨美迪西(688202.SH)近期在接待機構投資者調研時表示,公司擁有全面的臨牀前新藥研發能力及豐富的研發經驗。公司是國內少有的,能提供從先導化合物篩選、優化、原料藥製備、製劑工藝開發、藥效學研究到臨牀前藥代動力學及藥物安全性評價等一系列服務的綜合性CRO。2015年至2022年末,公司參與研發完成的新藥及仿製藥項目已有330件通過NMPA、美國FDA、澳大利亞TGA的審批進入臨牀試驗。

其次,公司在免疫腫瘤藥物、抗體及抗體偶聯藥物研發領域具有相對優勢。公司系統地建立超過330種腫瘤模型,長期為國際大型抗腫瘤藥物公司武田製藥等客户提供抗腫瘤藥物研究服務,並且在抗體及抗體偶聯藥物的研發領域具有較為豐富的經驗,已幫助客户完成數個抗體及抗體藥物偶聯物(ADC)的整套臨牀前研究,其中14件ADC藥物的藥代和安全性評價研究已通過NMPA、FDA技術審評並進入臨牀試驗階段。同時,公司也具備專業人才團隊優勢,建立了具有國際標準的研究質量控制體系,擁有優質的客户羣和良好的行業口碑,並且緊跟新藥研發趨勢,持續創新藥物研發關鍵技術。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account